News
SCNX
0.3779
+0.64%
0.0024
Weekly Report: what happened at SCNX last week (0608-0612)?
Weekly Report · 3h ago
Scienture says large national health plan adds REZENOPY naloxone spray to formulary
PUBT · 6d ago
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Benzinga · 6d ago
EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July
Benzinga · 6d ago
Weekly Report: what happened at SCNX last week (0601-0605)?
Weekly Report · 06/08 09:34
Scienture reveives U.S. patent covering Rezenopy Nasal Spray
TipRanks · 06/02 15:04
Scienture wins US patent for REZENOPY naloxone nasal spray, protection through 2041
PUBT · 06/02 12:09
SCIENTURE RECEIVES U.S. PATENT COVERING REZENOPY™ (NALOXONE HCL) NASAL SPRAY 10 MG, STRENGTHENING INTELLECTUAL PROPERTY PROTECTION THROUGH 2041
Reuters · 06/02 12:05
Weekly Report: what happened at SCNX last week (0525-0529)?
Weekly Report · 06/01 09:37
Scienture Holdings Announces CFO Resignation, Names Interim Successor
TipRanks · 05/29 22:42
Scienture Eric Sherb Resigns As CFO Effective May 26, 2026; Narasimhan Mani Appointed As Interim CFO Effective May 26, 2026
Benzinga · 05/29 21:09
SCIENTURE - APPOINTS NARASIMHAN MANI AS INTERIM CFO EFFECTIVE MAY 26, 2026 - SEC FILING
Reuters · 05/29 21:02
Scienture names Narasimhan Mani interim CFO after Eric Sherb resigns
PUBT · 05/29 21:01
Weekly Report: what happened at SCNX last week (0518-0522)?
Weekly Report · 05/25 09:38
Scienture Holdings, Inc. GAAP EPS of -$0.08 beats by $0.15, revenue of $0.06M
Seeking Alpha · 05/18 18:02
Scienture Holdings Q1 revenue jumps on Arbli sales, operating expenses steady
Reuters · 05/18 12:47
SCIENTURE REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE HIGHLIGHTED BY SIGNIFICANT REVENUE GROWTH AND GROSS MARGIN EXPANSION
Reuters · 05/18 12:38
SCIENTURE HOLDINGS, INC Q1 GROSS PROFIT USD 54 THOUSAND
Reuters · 05/18 12:38
Weekly Report: what happened at SCNX last week (0511-0515)?
Weekly Report · 05/18 09:38
Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY
Benzinga · 05/15 22:12
More
Webull provides a variety of real-time SCNX stock news. You can receive the latest news about Scienture Holdings, Inc through multiple platforms. This information may help you make smarter investment decisions.
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.